Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S. Food and Drug Administration (FDA) has approved ROMVIMZA™ (vimseltinib), a kinase ...
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; "Ono") announced that the U.S. Food and Drug Administration (FDA) has approved ROMVIMZAtm (vimseltinib), a kinase ...
Rare cancers are less known and pose challenges due to limited research and diagnostic difficulties. Environmental factors, ...
in patients with metastatic colorectal cancer (mCRC) treated with telisotuzumab adizutecan (ABBV-400). This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This ...
Citalopram exhibits immune-dependent anti-tumor effects by modulating C5aR1 + TAMs and CD8 + T cells
In addition to their previous report on directly targeting tumor cells via glucose transporter 1 (GLUT1), they tried to uncover additional working mechanisms of citalopram in HCC treatment in the ...
Gastrointestinal stromal tumors (GIST ... with greater specificity for targeting particular components of the cancer cell have become possible. Nonetheless, in order to understand the complexity ...
It feels like the Splinter Cell remake has been on its way for a while now, which isn't helped by the fact it's been over three years since we heard anything official about the game. From what we ...
This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a full text component.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback